MOESM2 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Fuchigami, Ayako; Shigiyama, Fumika; Kitazawa, Toru; Okada, Yosuke; Ichijo, Takamasa; Higa, Mariko; Hiyoshi, Toru; Inoue, Ikuo; Iso, Kaoru; Yoshii, Hidenori; Hirose, Takahisa; Kumashiro, Naoki

doi:10.6084/m9.figshare.11543364.v1

12933_2019_977_MOESM2_ESM.doc (34 kB)

MOESM2 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

journal contribution

posted on 2020-01-08, 04:55 authored by Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose, Naoki Kumashiro

Additional file 2: Table S1. Adjusted risk of endpoints that affect the incidence of cardiovascular events.

Funding

AstraZeneca Japan K.K.

History

Usage metrics

Keywords

Type 2 diabetes Cardiometabolic risk factors Dapagliflozin Sitagliptin Glycemic control Weight loss Hypoglycemia

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM2 of Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

Funding

AstraZeneca Japan K.K.

History

Usage metrics

Categories

Keywords

Licence

Exports